“Our objective is to find new and effective methods to relieve anxiety and suffering, and contribute to the understanding of neuroscience and the relationship of the mind and body. This is a frontier of research that will shape our future in important ways that we are just beginning to appreciate.”
—Bill Linton, Co- Executive Director
Usona Institute is a 501(c)(3) non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to further the understanding of the therapeutic effects of psilocybin and other consciousness-expanding medicines. Our focus is on alleviating depression in people for whom current medical treatments fall short in offering relief and a better quality of life.
Based in Madison, Wisconsin, Usona was founded in 2014 by Bill Linton, CEO and Founder of the international life sciences company Promega Corporation, and Malynn Utzinger, M.D., Director of Integrative Practices at Promega Corporation. The Institute was founded shortly after Bill was inspired by the meaningful impact that a psilocybin study at Johns Hopkins University had on a friend suffering from cancer.
To learn more about how Usona came to be founded as a non-profit medical research organization, please see the video below featuring Co- Executive Director Malynn Utzinger, M.D.
The University of Wisconsin Hospital and Clinics
University of Wisconsin–Madison School of Pharmacy
The Heffter Research Institute
The Swiss Neuromatrix Foundation
Roland Griffiths, PhD, Johns Hopkins University School of Medicine
Matthew Johnson, PhD, Johns Hopkins University School of Medicine
Joshua Woolley, MD, PhD, UCSF School of Medicine
Brian Anderson, MD, UCSF School of Medicine
Charles Grob, MD, Harbor-UCLA Medical Center
Stephen Ross, MD, New York University (NYU)
Michael Bogenschutz, MD, New York University (NYU)
Franz Vollenweider, MD, University of Zürich
Benjamin Kelmendi, MD, Yale School of Medicine
Janis Phelps, PhD, CIIS Center for Psychedelic Therapies and Research
Statement on Collaboration
Usona Institute is able to accomplish its mission of enabling and supporting psychedelic research and FDA registration of psilocybin therapy only through collaboration with many scientists, clinicians, research centers, expert consultants, and philanthropists globally.
Usona will continue to build relationships and collaborations with all organizations that share our philosophy of delivering approved therapies to those in need based on safety, high quality active drug materials, and highly-trained guides and practitioners, at the lowest possible cost.
Usona is building an advanced chemistry capability with our cGMP contract suppliers and through approved research chemistry facilities at two locations in the United States. High quality materials will be supplied to qualified research and therapy centers for basic, applied, and clinical research at cost or gratis, for the purpose of accelerating the pace of research for these important therapies.
Expertise on the Usona team includes:
- Study design and protocol development
- ICH GCP (Good Clinical Practice) compliance
- FDA drug development
- Clinical research leadership
- Multi-site drug development management
- Contract research organization (CRO) management
- CIIS-trained guide expertise
- Complex clinical drug development program management
- Small molecule design and scale-up with full analytical capabilities
- Preclinical safety and pharmacology research
- Translational methodologies
- Navigation of regulatory agencies and requirements
- Public health policy
Per the policy adopted by its Board of Directors, Usona Institute will reimburse indirect costs at a rate of up to 22.5% for clinical research, and a rate of up to 15% for non-clinical research. This policy does not apply to gifts made to research institutions and/or affiliated non-profit entities, which are to be used only toward direct costs.